The number one ingredient that an oncology-based alternative payment model needs to succeed is collaboration, explained Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance (COA).
The number one ingredient that an oncology-based alternative payment model (APM) need to succeed is collaboration, working with stakeholders, participants, and practices, explained Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.
Transcript
What are some potential value-based care qualities that an oncology-focused APM needs to succeed and have significant enrollment?
I think the number one ingredient that an oncology-based APM needs to have to succeed—whether this is government-driven, private, through an insurer—needs to be collaboration and working with the stakeholders and participants, particularly the practices. They are the ones these days, especially with downside risk, who have to have the most “skin in the game.” You are asking them to take significant risks that sometimes could be practice ending if they are not able to manage costs and manage patient care.
So, you need to have a collaborative discussion with them and with all the stakeholders in the community about what the model looks like, what are the inputs, what are the variables that they can control, and how the everyone in the entire ecosystem can work together to succeed.
The EOM [Enhancing Oncology Model] is something that we at the Community Oncology Alliance were a little concerned about. In the lead up to it, there were significant questions about its structure and particularly the downside risk that they had to enter into immediately. The [small] number of practices that signed up was clearly an indicator of that concern.
We had polled our practices and surveyed our practices before the EOM launched and saw a significant level of concern from them. And then the numbers of practices that ended up past the starting point in the official model really showed that out.
The lack of practices that carried over from the OCM [Oncology Care Model] to the EOM, I think, is a really, really incredible and scary indicator for the promise of where this might go. Granted, we're still very early in the program, there's still a lot to see, and we're not hearing a ton right now about practices ready to leave immediately. But there still remains a significant concern [and] significant skepticism around this program.
Another element of the EOM that I think practices are very concerned about is health equity. It’s really wonderful for us to know that health disparities exist, that some of our patients may be homeless or food insecure or experiencing others other forms of systemic inequities in cancer care. But there's a big difference between knowing about a problem and doing something about that problem.
We've all been in that position where we have seen something or someone that we want to help and been unable to do that. Now, put yourself in the shoes of an oncologist who sees a patient, who's told that they're homeless or they can't feed themselves or they can't feed their dogs. Those are very real things that community oncologists face every day.
CMS has done a great job of building the structure and indicating that we're going to go to a place where we can track and report and measure those things. But they are not offering any solutions for how we actually address those things and any additional payments that practices are going to be able to get to do that. In fact, it cut the MEOS [Monthly Enhanced Oncology Services] payments [that OCM had]. So, that is an area where I think you're going to see significant concern from practices; one that we're seeing already.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More